| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02872649 2010-024534-38 Details | 2016-08-19 Interventional | 2 | 16 | Dabigatran Phenprocoumon Warfarin Thrombosis Bleeding | safety reasons - | |||
| NCT02103166 2013-001921-19 Details | 2016-08-19 Interventional | 4 | - | Bromides Scopolamine Labor, First St… | Conditions of recruitment changed - | |||
| NCT01405846 2010-023355-29 Details | 2016-08-19 Interventional | 2 | 32 | Gefitinib Head and Neck N… Head and Neck C… Lung Cancer | Futility - | |||
| NCT01937715 2013-002096-18 Details | 2016-08-18 Interventional | 1/2 | 18 | Bevacizumab Gedatolisib Colorectal Neop… Metastatic Colo… | B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the
portfolio and is not due to any safety concerns or regulatory interaction As this study was terminated due to Pfizer portfolio prioritization prior to the Phase 2 portion, there are no efficacy evaluations for Phase 2. | |||
| NCT00750581 Details | 2016-08-18 Interventional | 2/3 | 9 | Indomethacin Ductus Arterios… Patent Ductus A… | Study medication was no longer available for study - | |||
| NCT00814164 Details | 2016-08-17 Interventional | 2 | 21 | Clofarabine Daunorubicin Leukemia Leukemia, Myelo… Leukemia, Myelo… | Sponsor withdrew support - | |||
| NCT00442416 Details | 2016-08-17 Interventional | 3 | 80 | Epoetin Alfa Anemia | Strategic decision unrelated to safety or efficacy The study was prematurely terminated during enrollment period due to legal reasons. Therefore, the planned statistical analysis of the primary endpoint was not performed. | |||
| NCT01217632 Details | 2016-08-16 Interventional | 2 | 114 | Entecavir Communicable Di… Fibrosis Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Infections Liver Cirrhosis Liver Fibrosis … | Study terminated due to an unexpected prominent effect of entecavir alone in this patient
population. - | |||
| NCT02654405 Details | 2016-08-15 Interventional | 2/3 | 0 | Butyric Acid Schizophrenia Cognitive Funct… Schizophrenic D… | Nathan Kline Institute (NKI) decided not to accept study grant from Stanley Medical Research
Foundation. because of budget considerations. - | |||
| NCT01035255 2009-015834-31 Details | 2016-08-15 Interventional | 3 | 8442 | Enalapril Sacubitril and … Heart Failure Heart Failure W… | Early termination was approved due to compelling efficacy of LCZ696 in patients with HF &
reduced EF after final pre-specified interim analysis 28-Mar-2014. - | |||
| NCT00133029 Details | 2016-08-15 Interventional | 4 | - | Anti-Bacterial … Cesarean Sectio… | - - | |||
| NCT00116623 Details | 2016-08-15 Interventional | 4 | - | Indomethacin Magnesium Sulfa… Obstetric Labor… Labor, Prematur… | Funding completed - | |||
| NCT01871532 2012-003227-38 Details | 2016-08-11 Interventional | 4 | 24 | Follicle Stimul… Infertility Monofollicular … | Study was terminated because of delays in sourcing replacement Investigational Medicinal
Product for the study due to manufacturing delays. Study was terminated because of delays in sourcing replacement Investigational Medicinal Product (IMP) for the study due to manufacturing delays hence the outcome measure was not assessed. | |||
| NCT02539017 Details | 2016-08-10 Interventional | 2 | 0 | Immunomodulatin… Breast Neoplasm… Triple Negative… | because of safety problem, this trial was stopped in the hospital - | |||
| NCT01029639 Details | 2016-08-10 Interventional | 2/3 | 0 | Insulin Insulin Aspart Insulin, Globin… Hypoglycemia | Administrative - | |||
| NCT00967837 Details | 2016-08-10 Interventional | 2/3 | 152 | Insulin Insulin, Globin… Wounds and Inju… Diabetes Wound Healing | Administrative - | |||
| NCT00539435 Details | 2016-08-10 Interventional | 3 | 0 | Insulin Insulin Aspart Diabetes Mellit… Heart Diseases Diabetes Mellit… | Administrative - | |||
| NCT00539409 Details | 2016-08-10 Interventional | 2/3 | 152 | Insulin Insulin Aspart Insulin, Globin… Diabetes Mellit… Diabetes Mellit… | Administrative - | |||
| NCT00287651 Details | 2016-08-10 Interventional | 2/3 | 150 | Insulin Insulin, Globin… Diabetes Mellit… Diabetic Retino… Diabetes Mellit… | Administrative - | |||
| NCT00228904 Details | 2016-08-10 Interventional | 2/3 | 0 | Insulin Insulin Aspart Insulin Lispro Insulin, Globin… Diabetic Neurop… Peripheral Nerv… Diabetic Neurop… | Administrative - |